March 2016 News Recap

START Center Aims to Bring New Cancer Treatments, Trials to The Community

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD

APPs Bridging Science and Care: Understanding and Advocating for Bispecifics in Later Line Multiple Myeloma

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD

August 18th 2025

Elranatamab and MagnetisMM-3 Results are Superior to Real-World Multiple Myeloma Outcomes

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Tackling Unmet Needs in Mantle Cell Lymphoma

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.

Tycel Phillips, MD

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Tycel Phillips, MD, highlighted the need for new therapies for patients with MCL who have relapsed on previous lines of treatment.

Related Content

START Center Aims to Bring New Cancer Treatments, Trials to The Community

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD

APPs Bridging Science and Care: Understanding and Advocating for Bispecifics in Later Line Multiple Myeloma

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD

August 18th 2025

Elranatamab and MagnetisMM-3 Results are Superior to Real-World Multiple Myeloma Outcomes

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Tackling Unmet Needs in Mantle Cell Lymphoma

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.

Tycel Phillips, MD